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Summary
Several host factors have been implicated in resistance to HIV infection in
individuals who remain HIV-seronegative despite exposure. In a cohort of
HIV-serodiscordant heterosexual couples, we investigated interactions
between systemic inflammation and T-cell activation in resistance to HIV
infection. Males and females in stable long-term relationships with either
HIV-infected or uninfected partners were recruited, blood T-cell activa-
tion (CD38, HLA-DR, CCR5 and Ki67) and plasma cytokine concentra-
tions were evaluated. The HIV-negative exposed individuals had
significantly lower frequencies of CCR5+ CD4+ and CD8+ T cells than
unexposed individuals. Mean fluorescence intensity of CCR5 expression
on CD4+ T cells was significantly lower in HIV-negative exposed than
unexposed individuals. Protective CCR5 haplotypes (HHA/HHF*2,
HHF*2/HHF*2, HHC/HHF*2, HHA/HHA, HHA/HHC and HHA/HHD)
tended to be over-represented in exposed compared with unexposed indi-
viduals (38% versus 28%, P = 058) whereas deleterious genotypes (HHC/
HHD, HHC/HHE, HHD/HHE, HHD/HHD and HHE/HHE) were under-
represented (26% versus 44%; P = 016). Plasma concentrations of inter-
leukin-2 (P = 002), interferon-c (P = 005) and granulocyte–macrophage
colony-stimulating factor (P = 0006) were lower in exposed compared
with unexposed individuals. Activation marker expression and systemic
cytokine concentrations were not influenced by gender. We conclude that
the dominant signature of resistance to HIV infection in this cohort of
exposed but uninfected individuals was lower T-cell CCR5 expression and
plasma cytokine concentrations.
Keywords: CCR5; HIV; immune activation; resistance.
Abbreviation: ACD, acid citrate dextrose; AIDS, acquired immunodeficiency syndrome; CCR5, C-C chemokine receptor type 5;
CD, cluster of differentiation; GM-CSF, granulocyte-macrophage colony-stimulating factor; HIV, human immunodeficiency
virus; IFN-c, interferon gamma; IL-2, interleukin-2; ORF, open reading frame; PBMC, peripheral blood mononuclear cell; PCR,
polymerase chain reaction; RANTES, Regulated on Activation, Normal T Cell Expressed and Secreted; SNP, single nucleotide
polymorphism; TNF-a, tumor necrosis factor-alpha; Treg, regulatory T cell
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Introduction
Important insights into mechanisms underlying resistance
to HIV infection have come from studies in exposed–
uninfected individuals. Although HIV transmission is
inefficient, substantial efforts have focused on identifying
co-factors enhancing infection and defining potential cor-
relates of protection, relevant to the design of HIV pre-
vention strategies. As such, key populations including
commercial sex workers,1 HIV-serodiscordant couples,2–4
injectable drug users,5 infants born to HIV-infected
mothers,6 occupational exposure in healthcare workers7
and men having sex with men8 have provided some
important clues.
Although the mechanisms of protection from HIV
infection in HIV-exposed individuals have been investi-
gated, they are likely to be multifactorial and remain lar-
gely undefined. Several host factors have been associated
with protection against HIV infection in these individuals;
such as: CCR5 co-receptor susceptibility,9 certain innate
and adaptive immune responses;10,11 and cytokines
(RANTES, secretory leucocyte protease inhibitor 1,
macrophage inflammatory protein-1a and macrophage
inflammatory protein-1b).12,13 In addition, higher
frequencies of HIV-specific interferon-c (IFN-c) and
interleukin-2 (IL-2) -secreting T cells were found in
HIV-exposed–uninfected individuals than unexposed
individuals.14,15
Lower levels of immune activation and immunological
quiescence are strongly associated with resistance to HIV
infection in exposed–uninfected individuals.16–19 In addi-
tion, specific CCR5 genotypes have been associated with
resistance/protection from HIV infection. This includes
the CCR5D32 genotype, characterized by a 32-bp deletion
in the CCR5 open reading frame (ORF), directly impact-
ing on both susceptibility to HIV-1 infection and rate of
disease progression.20,21 CCR5 receptor density, linked to
CCR5 genotype, exerts a direct influence on susceptibility
to HIV infection.20,22 In addition to CCR5D32 genotype,
multiple other CCR5 ORF mutations, single nucleotide
polymorphisms (SNPs) and/or haplotypes in the CCR5
regulatory/promoter region have been shown to be cap-
able of influencing CCR5 receptor density; hence HIV
susceptibility and rate of disease progression.23–26
Card et al.27 suggested that lower levels of immune
activation in individuals resistant to HIV infection were
associated with higher frequencies of regulatory T (Treg)
cells. Although lower levels of immune activation are
associated with resistance to HIV infection, the mecha-
nism for the long-term maintenance of the low levels of
immune activation has yet to be identified. In this study,
we investigated the interaction between systemic inflam-
mation (measured by soluble cytokine concentrations),
immune activation of T cells and the influence of CCR5
genotype in resistance to HIV infection in HIV-exposed




Two hundred and fifteen HIV-negative black South Afri-
can men and women who were in stable long-term
heterosexual relationships were recruited from the Empil-
isweni Clinic in Gugulethu, Cape Town.28,29 HIV-positive
participants had to be naive to therapy to be eligible for
enrolment. Of the couples enrolled, 48% (103/215) of
couples included partners who were both HIV-negative
(unexposed) and 52% (112/215) included HIV serodis-
cordant partners where one was HIV-positive (HIV-
exposed). The study was approved by the Faculty of
Health Sciences Human Research Ethics Committee of
the University of Cape Town and informed written con-
sent was obtained from all individuals before enrolment.
Specimen collection and processing
Blood (16 ml) was collected by venepuncture into sterile
ACD anti-coagulated vacutainer tubes (BD Biosciences,
Plymouth, UK) and processed within 4 hr of collection.
Peripheral blood mononuclear cells (PBMCs) were iso-
lated using Ficoll-Hypaque (Sigma-Aldrich, St Louis,
MO) density gradient centrifugation in Leucosep tubes,
and cryopreserved in liquid nitrogen. Plasma was
split into aliquots and preserved at 80° for cytokine
measurement.
Measurement of cytokine concentrations in plasma
The concentrations of IL-1b, IL-6, IL-12p70, tumour
necrosis factor-a (TNF-a), IL-10, IL-2, IFN-c, IL-7
and granulocyte–macrophage colony-stimulating factor
(GM-CSF) were measured in blood plasma using High
Sensitivity Human Cytokine LINCOplex kits (sensitivity
range: 001–048 pg/ml; LINCO Research, St Charles,
MO). Interplate variation for cytokines was measured by
the inclusion of duplicates for 76 samples, distributed
across the seven plates assayed. Spearman rank correlation
coefficients were used to assess degree of variation, with
the least deviation seen for IL-1b (R2 = 096, P < 00001)
and the most for IL-12p70 (R2 = 038, P = 00007; see
Supplementary material, Table S1). Data were collected
using a Bio-PlexTM Suspension Array Reader (Bio-Rad
Laboratories Inc, Minneapolis, MN) and a 5 PL regres-
sion formula was used to calculate cytokine concentra-
tions from the standard curves. Data were analysed using
BIO-PLEX MANAGER software (version 4; Bio-Rad Laborato-
ries Inc.). Cytokine concentrations that were below the
detection limit of the assay were reported as the
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mid-point between the lowest concentration measured for
each cytokine and zero.
Staining for markers of T-cell activation by flow
cytometry
Thawed PBMCs from a convenient subset of 38/103 HIV-
unexposed and 30/112 HIV-exposed–uninfected individu-
als were stained and 1 million PBMCs were used per
staining reaction per participant.30 PBMCs were incu-
bated with LIVE/DEAD Fixable Violet Dead Cell Stain
for 20 min at room temperature, then washed with 1%
fetal calf serum (FCS) -supplemented PBS. The pelleted
cells were resuspended in a dead volume and stained for
30 min at room temperature with phenotypic marker
peridinin chlorophyll protein-Cy5.5 labelled anti-CD4
(Clone SK7; BD Pharmingen, San Jose, CA), QDot605-
labelled anti-CD8 (Clone 3B5; Invitrogen, Carlsbad, CA),
allophycocyanin-labelled anti-CD195/CCR5 (Clone 2D7;
BD Biosciences, San Jose, CA), phycoerythrin-
Cy7-labelled anti-CD38 (Clone HB7; BD Biosciences),
phycoerythrin-labelled anti-HLA-DR (Clone L243; BD
Biosciences), and finally Pacific Blue-labelled anti-CD14
(Clone M5E2; BD Pharmingen) and anti-CD19 (Clone
SJ25-C1; Invitrogen). Anti-CD14 and anti-CD19 antibod-
ies were included as dump markers to exclude monocytes
and B cells from analysis, respectively. Cells were then
washed twice with 1% FCS-supplemented PBS, fixed and
permeabilized with BD CytoPerm/CytoFix (BD Bio-
sciences) for 20 min at room temperature. Cells were
washed with Perm/Wash buffer (BD Biosciences) and
stained intracellularly with allophycocyanin-H7-labelled
anti-CD3 (Clone SK7; BD Biosciences) and FITC-labelled
anti-Ki67 (BD Biosciences; Clone B56). Cells were washed
and fixed with BD Cell Fix (BD Biosciences). Cell fluores-
cence was assessed using a BD LSR Fortessa flow cytome-
ter (BD Immunocytometry Systems, San Jose, CA).
Fluorescence minus one was used to distinguish continu-
ous populations. Compensation and analysis of data were
performed using FLOWJO software (Tree Star, Ashland,
OR). For the gating strategy: cell doublets/aggregates were
removed by gating on singlets. Live CD3+ T-cell popula-
tions were differentiated into CD4+ and CD8+ T-cell sub-
sets. Overall expression frequencies of activation markers
as well as those of the permutations of expression that
contributed to that frequency were then evaluated for
CD4+ and CD8+, respectively.
CCR5 genotyping and haplotype assignment
Individuals were genotyped as described previously.31
Genomic DNA was extracted from PBMC samples; a con-
tinuous region encompassing the CCR5 ORF and the
promoter 1 region was PCR amplified in overlapping sec-
tions using Expand High Fidelity PCR System (Roche,
Mannheim, Germany) and sequenced using BigDye Ter-
minator version 31 chemistry (Applied Biosystems, Fos-
ter City, CA). Sequenced fragments were electrophoresed
using the automated 3100 Genetic Analyzer (Applied
Biosystems) and HAPLOTYPER software was used to
infer haplotypes.32
CCR5 -4223 C/T SNP genotyping
A real-time SYBR green CT (cycle threshold)-shift assay
was designed to genotype the CCR5 -4223 C/T SNP
reported to disrupt the CpG -41 site.19 Primer sequences
were as follows (square brackets denote lock nucleic acid
modified nucleotides), C allele-specific reverse primer: 5ˈ-
CCATTTCCTCATCTGTTAAATGAC[G]-3ˈ; T allele-specific
reverse primer: 5ˈ-CCATTTCCTCATCTGTTAAATGAC
[A]-3ˈ; common forward primer: 5ˈ-GTGGAGTAACGCA-
CACTGCAA-3ˈ. Hence, two PCR were conducted per
sample, one with each allele-specific primer. PCR were
run in an Applied Biosystems 7500 Real-Time PCR sys-
tem. To analyse the PCR data, the difference in CT of
the two reactions was calculated, in a heterozygous indi-
vidual, both PCR should amplify similarly with minimal
CT difference (fewer than two cycles in this assay) and
in homozygous wild-type (C allele) individuals a CT dif-
ference of eight or more cycles was consistently attained.
Homozygosity for the mutant allele (T) was not
observed.
Statistical analysis
Comparison of unpaired responses was performed using
the Mann–Whitney U-test. Statistical inferences on binary
outcomes were performed using the Fisher’s exact test.
All tests were two-tailed and P-values of ≤ 005 were con-
sidered significant. Adjustment for multiple comparisons
was performed using a false discovery rate step-down
approach. Statistical analyses were performed using GRAPH-
PAD PRISM version 50 for Windows (GraphPad Software,
San Diego, CA) and STATATM (version 11, StataCorp, Col-
lege Station, TX).
Result
Two hundred and fifteen HIV-negative men and women
and their long-term heterosexual partners were included
to investigate the role of sexual partner HIV status on
systemic immune activation, CCR5 haplotype and expres-
sion, and inflammation in South African individuals, as
potential correlates of HIV risk or protection (Table 1).
Of these, 48% (103/215) were HIV-negative unexposed
(stable partners also HIV-negative) and 52% (112/215)
were HIV-negative but exposed to HIV (partners were
HIV-positive). All couples were black South African isiX-
hosa speaking individuals. HIV-negative exposed
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individuals were more likely to be men (73% versus 50%;
P = 0001) in this cohort and were slightly older than
HIV-unexposed individuals (40 versus 36; P = 001;
Table 1). The age difference is expected because signifi-
cantly more men were enrolled in the exposed group, and
overall men were older than women (40 versus 36 years;
P = 002). In addition, HIV-negative exposed individuals
reported having had a longer sexual history than their
HIV-negative unexposed counterparts (21 versus 19 years;
P = 001; Table 1) and, although age at sexual debut did
not differ significantly between the groups, exposed indi-
viduals did tend to have initiated sexual activity at a
younger age (17 versus 18 years; P = 020; Table 1). HIV-
unexposed individuals reported higher frequencies of sex
acts in the last month and lower frequencies of condom
use than HIV-exposed individuals. The significantly
higher condom usage among discordant couples was not
surprising as couple-based counselling would have
informed these participants about risk-reducing beha-
viours. CD4 percentages, proportion of individuals
cohabiting, or having either ulceration or discharge were
similar in HIV-negative exposed and unexposed
individuals (Table 1). All the men included in this study
had undergone traditional isiXhosa circumcision.
Partner HIV status and systemic cytokines
The concentrations of TNF-a, IL-b, IL-6, IL-10, IL-7,
GM-CSF, IL-12p70, IL-2 and IFN-c were measured in
plasma from HIV-negative exposed and unexposed indi-
viduals (Table 2). Concentrations of adaptive cytokines
IL-2 (P = 002) and IFN-c (P = 005), and haematopoi-
etic GM-CSF (P = 0006) were significantly lower in
exposed compared with unexposed individuals. Differ-
ences in GM-CSF remained significant after adjustment
for multiple comparisons. No significant differences were
observed in inflammatory cytokines (IL-b, IL-6, IL-12p70,
TNF-a) between the groups. Although exposed individu-
als were more likely to be men, gender did not signifi-
cantly influence concentrations of systemic cytokines
(Table 2).
More than half (57%) of the HIV-positive partners in
this study had plasma HIV loads > 1500 cps/ml (data not
shown), and so would be considered ‘infectious’ to their
Table 1. Clinical and socio-behavioural characteristics of participants
Characteristics Unexposed Exposed P-value
Male [% (n/N)] 49 (50/103) 65 (73/112) 0001
Age [year; median (IQR)] 36 (29–43) 40 (33–48) 001
Living together with partner [% (n/N)] 72 (74/103) 56 (63/112) 02
Age at first sex [median (IQR)] 18 (16–18) 17 (15–18) 02
Sexual exposure [median years of sex (IQR)] 19 (12–26) 21 (17–30) 001
Blood CD4% [median (IQR)] 71 (59–86) 74 (61–81) 09
Sex acts in the last month [median (IQR)] 4 (3–8) 3 (2–5) 0004
Condom usage [% (n/N)] 29 (27/921) 75 (77/1021) < 00001
Genital ulceration in the last 6 months [% (n/N)] 2 (2/931) 5 (5/1111) 05
Vaginal discharge in the last 6 months [% (n/N)] 6 (3/511) 10 (3/301) 05
1Number of responses for each characteristic varied based on availability of data in participants’ folders and samples in the repository.
IQR, Interquartile range.
Table 2. Impact of partner HIV status and gender on plasma cytokine concentrations
Function Cytokine
Median cytokine conc (IQR; pg/ml)
P-value
Median cytokine conc (IQR; pg/ml)
P-valueUnexposed (n = 103) Exposed (n = 112) Male (n = 123) Female (n = 92)
Inflammatory IL-b 045 (007–143) 035 (004–125) 05 031 (0028–118) 050 (010–150) 082
IL-6 466 (236–787) 390 (175–750) 02 377 (181–801) 466 (275–704) 090
IL-12p70 0005 (0005–083) 0005 (0005–058) 08 0005 (0005–050) 0005 (0005–115) 044
TNF-a 600 (394–814) 585 (402–778) 07 620 (408–806) 532 (395–757) 007
Regulatory IL-10 1043 (560–2226) 908 (588–1795) 07 968 (587–1825) 1001 (575–2241) 055
Adaptive IL-2 028 (0005–103) 0008 (0005–069) 002 003 (0005–067) 032 (0005–131) 097
IFN-c 094 (014–291) 064 (002–193) 005 064 (002–219) 083 (016–259) 021
Haematopoietic IL-7 186 (068–349) 151 (069–346) 07 149 (068–313) 200 (071–380) 054
GM-CSF 064 (020–146) 032 (012–082) 0006 035 (0098–082) 070 (021–147) 014
Mann–Whitney U-tests were applied to compare cytokine concentrations between groups.
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HIV-negative partners, according to the estimates pub-
lished by Quinn et al.33 Several plasma cytokines were
positively associated with male partners’ plasma HIV
loads [IFN-c (r = 044, P = 0018), IL-2 (r = 043,
P = 0021), IL-6 (r = 044, P = 0018), IL-7 (r = 056,
P = 0002), IL-12p70 (r = 039, P = 0041) and GM-CSF
(r = 041, P = 029)].
Partner HIV status and T-cell activation
CCR5, CD38, HLA-DR and Ki67 expression by CD4+
and CD8+ T cells were compared individually or in bio-
logically relevant combinations [HLA-DR+ CD38+ (repre-
senting highly activated T cells), Ki67+ CCR5+
(representing proliferating T cells, which may be suscepti-
ble to HIV infection), CD38+ CCR5+ (representing sus-
ceptible, activated T cells) and CD38+ Ki67+
(representing activated, proliferating T-cells)] in exposed
versus unexposed individuals to investigate the relation-
ship between partner status and activation of T cells in
HIV-negative individuals (Fig. 1a–d). HIV-exposed indi-
viduals had significantly lower frequencies of CD4+ T
cells expressing the HIV co-receptor CCR5, alone or in
combination with Ki67 or CD38, than unexposed individ-
uals (P = 0007 for CCR5 alone, P = 0001 for
CCR5+ Ki67+ and P = 0005 for CCR5+ CD38+; Fig. 1a,
c). All of these comparisons remained significantly differ-
ent after adjusting for the potential contributions of con-
founding variables age, gender and condom use. These
data suggest that lower frequencies of activated and pro-
liferating CCR5+ CD4+ T cells may be potentially induced
by HIV exposure in those protected from HIV infection
by their HIV-positive partners.
Similarly, HIV-negative exposed individuals had signifi-
cantly lower frequencies of CCR5, alone or in combina-
tion with Ki67 and CD38, on the surface of their CD8+ T
cells than their unexposed counterparts (P = 0007 for
CCR5 alone, P = 00003 for CCR5+ Ki67+, P = 0003 for
CCR5+ CD38+; Fig. 1b,d). These differences remained
significantly different for CCR5 alone and CCR5+ CD38+
after adjusting for age, gender and condom usage. HIV-
negative exposed individuals also had lower frequencies
of CD8+ T cells expressing HLA-DR than HIV-negative
unexposed individuals (P = 004; Fig. 1b). Furthermore,
CCR5 mean fluorescence intensity was lower in HIV-
exposed than unexposed individuals, significantly so for
CD4+ T cells (P = 004 for CD4+ and P = 007 for CD8+
T-cell subsets, Fig. 2). This suggests that HIV-exposed
individuals had significantly fewer CD4+ CCR5+ T cells,
which also expressed significantly lower amounts of
CCR5 than unexposed individuals. Activation marker
expression was similar in men and women (Fig. 3). No
association was found between T-cell activation, prolifera-
tion or CCR5 expression by HIV-negative women’s cells
and partner’s plasma HIV load (data not shown).
Together with the cytokine data, this suggests that the
protection conferred in HIV-negative partners could be
the result of both HIV exposure and a natural resistance
in the form of a lowered CCR5 expression.
CCR5 polymorphisms and CCR5 expression
As particular CCR5 polymorphisms have been associated
with susceptibility to HIV infection, we evaluated the
haplotype and genotype distribution of CCR5 in this
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Figure 1. Impact of partner HIV status on
specific T-cell activation (expression of CD38,
HLA-DR, or Ki67) and CCR5 expression in
HIV-unexposed (open) versus HIV exposed–
uninfected (shaded) individuals. Frequency of
specific activation marker expression (Ki67,
HLA-DR, CD38) and CCR5 expression on
CD4+ (a and c) and CD8+ (b and d) T cells
derived from the blood of HIV-exposed
(n = 30) and unexposed (n = 38) was assayed.
The % of T cells in each group of individuals
is depicted by box-and-whisker plots indicating
the median (middle line), 25th (bottom line)
and 75th centiles (top line), and the range
(whiskers) of the frequencies of T cells express-
ing the respective activation markers. Assess-
ments of differences between exposed and
unexposed participants were carried out using
the Mann–Whitney U-test.
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mutation associated with deficient expression of CCR5
and HIV resistance. The most common haplotypes
(Fig. 4a) in exposed individuals were HHA (24%), HHC
(21%) and HHE (21%), although the most common in
unexposed individuals were HHE (28%), HHA (22%)
and HHD (19%). Based on CCR5 haplotyping, individu-
als were categorized into one of three categories defined
as haplotype pairs exhibiting: (i) protective genotypes
(HHA/HHF*2, HHF*2HHF*2, HHC/HHF*2, HHA/
HHA, HHA/HHC and HHA/HHD), (ii) deleterious geno-
types (HHC/HHD, HHC/HHE, HHD/HHE, HHD/HHD
and HHE/HHE), and (iii) neutral genotypes (with no
described phenotype in the context of HIV-1 infection,
and including any combination not considered protective
or deleterious). Protective genotypes were defined as
haplotype pairs associated with decreased HIV-1 suscepti-
bility and/or slower disease progression; deleterious geno-
types were defined as haplotype pairs associated with
faster disease progression to AIDS and death and/or
increased susceptibility to HIV-1 infection; and haplotype
pairs for which there were no designated disease altering
effects were reported as neutral.34 HIV-exposed partici-
pants had a greater proportion of individuals with protec-
tive genotypes than unexposed individuals (38% versus
28%, respectively; P = 058, Fig. 4b) compared with those
with deleterious genotypes (26% versus 44%; P = 018,
Fig. 4b) and a larger proportion of genotypes designated
as neutral (36% versus 28%; P = 059, Fig. 4b).
Haplotype HHA has been associated with slower disease
progression in African American individuals,24 whereas
haplotype HHE has been linked to an increased risk of
HIV-1 acquisition and a faster disease progression in popu-
lations that were ethnically divergent.26,35,36 Therefore, the
potential impact of the presence or absence of the HHA and
HHE haplotypes on CCR5 expression on T cells was investi-
gated. Haplotypes HHA and HHE did not significantly
impact CCR5 expression on CD4+ and CD8+ T cells,
although HHA+ individuals tended to have higher frequen-
cies of CCR5+ T cells compared with HHA– individuals
whereas HHE+ individuals tended to have lower CCR5+ T-
cell frequencies (Fig. 4c). As it is an individual’s genotype
(including the sum effects of the combination of CCR5 hap-
lotypes) that is likely to determine the overall CCR5 expres-
sion, CCR5 expression levels of individuals were compared
across defined phenotypes (protective, deleterious and neu-
tral). No significant differences were found when comparing
CCR5 expression levels on T cells across the three groups
(Fig. 4d), although individuals with protective CCR5 phe-
notypes tended to have higher frequencies of CCR5+ T cells
than those with deleterious CCR5 phenotypes.
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Figure 2. Impact of partner HIV status on density of CCR5 expres-
sion by T cells (measured by mean fluorescence intensity). The
cumulative MFI in each group of individuals is depicted by box-
and-whisker plots indicating the median (middle line), 25th (bottom
line) and 75th centiles (top line), and the range (whiskers). Assess-
ments of differences between exposed and unexposed participants
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Figure 3. Impact of gender on specific T-cell
activation (expression of CD38, HLA-DR, or
Ki67) and CCR5 expression. Frequency of
specific activation marker expression (Ki67,
HLA-DR, CD38) and CCR5 expression on
CD4+ (a and c) and CD8+ (b and d) T cells
derived from the blood of men and women
was assayed. The % of T cells in each group of
individuals is depicted by box-and-whisker
plots indicating the median (middle line), 25th
(bottom line) and 75th centiles (top line), and
the range (whiskers) of the frequencies of T
cells expressing the respective activation mark-
ers. Assessments of differences between men
and women was carried out using the Mann–
Whitney U-test.
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CCR5 -4223 C/T SNP genotyping
It was previously shown that the CCR5 4223C/T SNP,
which disrupts the CpG 41 site and alters the core con-
sensus motif of the CREB1-binding site of CCR5, is
uniquely present in persons from southern Africa, and
occurs on the background of the ancestral protective
HHA haplotype.19 This SNP showed a trend to over-
representation in individuals with reduced risk of acquir-
ing HIV-1 and in those with more effective control of
disease progression.19 We looked at the presence of this
particular genotype across our groups of exposed and
unexposed individuals. Exposed–uninfected individuals
had a higher representation of this SNP than unexposed
controls, although this was not significant (11% versus
5%, respectively, P = 070, data not shown). Furthermore,
the presence of this SNP did not impact on CCR5 expres-
sion (data not shown).
Discussion
HIV-exposed–uninfected individuals from South Africa
provide a unique opportunity to determine correlates of
protection associated with natural resistance to HIV
infection in a region with some of the highest HIV
prevalence and incidence rates globally. HIV serodiscor-
dant couples represent an important opportunity to study
correlates of protection, as exposure to HIV is more pre-
dictable than those who engage in high-risk behaviour
with partners unaware of their status. Here, we found
that these HIV-exposed–uninfected individuals had lower
frequencies of T cells expressing CCR5, lower densities of
CCR5 per cell, higher prevalence of protective CCR5
genotypes with lower prevalence of deleterious CCR5
genotypes, lower frequencies of activated CD38+ and
proliferating Ki67+ T cells, and lower concentrations of
certain adaptive (IL-2 and IFN-c) and haematopoietic
(GM-CSF) cytokines than their unexposed South African
counterparts, suggesting that those who remained unin-
fected had a smaller subset of HIV-susceptible target cells
compared with unexposed individuals.
CCR5 expression is central to productive HIV infection
of HIV target cells.37 A key difference between non-pro-
gressing primate hosts for simian immunodeficiency virus
infection (Sooty Mangabeys and African Green Monkeys)
and susceptible primate species (macaques and baboons)
was found to be comparatively reduced numbers of
CD4+ CCR5+ T cells in blood and lymphoid tissues
(bone marrow and lymph nodes).38 Paxton et al.9 linked






























































































































Figure 4. Distribution of CCR5 haplotypes and potential phenotypes across HIV-exposed and unexposed individuals and their association with
CCR5 expression level. (a) Distribution of CCR5 haplotypes previously described.24 (b) Distribution of phenotypes based on pre-established sets
of genotypes24,33 conferring protection (Protective), increased risks (Deleterious) or no effect (Neutral) in the context of HIV-1 infection and
AIDS disease. (c) Influence of HHA and HHE haplotypes on CCR5 expression within CD4+ and CD8+ T-cell subsets. Individuals with or without
an HHA allele were designated as HHA+ and HHA respectively. Individuals with or without an HHE allele were designated as HHE+ and
HHE, respectively. Matching CCR5 expression data and CCR5 haplotypes was available for 33 participants (n = 14 for HHA+, 19 for HHA,
16 for HHE+ and 17 for HHE). (d) Influence of protective, deleterious, or neutral CCR5 genotypes on CCR5 expression by CD4+ and CD8+
T-cell subsets.
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exposed–uninfected individuals to both attenuated
expression of CCR5 on T cells, and concurrent elevated
production of b-chemokines. Wu et al.39 showed that the
level of CCR5 expression correlated with the ability to
infect host cells with macrophage-tropic HIV in vitro.
Similarly, Blaak et al.40 confirmed that susceptibility of
activated PBMCs to infection with HIV was associ-
ated with levels of CCR5 expression and b-chemokine
production.
Although resistance to HIV infection has been attribu-
ted in some cohorts to homozygosity for the mutant alle-
les of the CCR5 receptor (CCR5D3241), this mutation is
present at very low frequencies in African populations.34
None of the individuals included in this study expressed
this mutant allele. We previously found marked differ-
ences in CCR5 haplotype prevalence and CCR5 expres-
sion in distinct South African populations,31,34,42 and that
specific CCR5 haplotypes were associated with reduced
CCR5 expression. CCR5 HHA haplotype has been sug-
gested to predict slower HIV disease progression in HIV-
1-infected individuals of African ancestry,24 and have the
lowest transcriptional activity in vitro.43 However, we
observed widely varying frequencies of CCR5 expression
in HHA+ and HHA individuals in this study that lar-
gely overlapped although median frequencies of T cells
expressing CCR5 tended to be higher in HHA+ than
HHA individuals. Gonzalez et al.24 argued that the
combined genotype (haplotype pairing rather than the
individual haplotypes of CCR5) is more likely to affect
the relationship between CCR5 phenotype and risk for
HIV infection or disease progression. In line with this, we
found that protective CCR5 genotypes (including HHA/
HHF*2, HHF*2HHF*2, HHC/HHF*2, HHA/HHA,
HHA/HHC and HHA/HHD34) were more prevalent
among HIV-exposed individuals than unexposed individ-
uals, whereas deleterious CCR5 genotypes (including
HHC/HHD, HHC/HHE, HHD/HHE, HHD/HHD and
HHE/HHE) were less prevalent. The southern African
CCR5 4223C/T SNP showed a trend to higher represen-
tation among high-risk HIV-exposed uninfected individu-
als and in those infected individuals with a better disease
outcome during HIV infection.19 Similarly, this SNP was
found at higher frequencies in this study in the HIV-
exposed compared with the unexposed individuals; how-
ever, this was not significant and did not impact on
CCR5 expression. These data collectively highlight the
importance of testing these CCR5 genetic variants on lar-
ger sample numbers – to establish their contribution to
protection from infection that also considers the extent of
immune activation as an epigenetic modifier influencing
risk of infection.
In addition to differences in CCR5 expression and geno-
types, we found that exposed individuals had reduced levels
of activated CD8+ T cells, marked by reduced expression of
HLA-DR, compared with unexposed individuals,
suggesting that immune-quiescence may have contributed
to protection in this cohort as proposed by others in
cohorts from Kenya,27,44 Central African Republic,17 Ivory
Coast,18 and the Netherlands.16 Clerici et al.45 suggested
that immune activation in individuals residing in Africa
was environmentally driven and not genetically pre-deter-
mined. Comparing HIV-negative Ugandans and Italians
residing in Italy with their counterparts living in Africa,
they showed that surface expression of CCR5 was higher in
those residing in Africa compared with those in Italy, irre-
spective of ancestry. They suggested that environmental
factors, such as parasites, other chronic infections, or nutri-
tion, might influence immune activation. Cohen et al.46
found that cervical T cells from Kenyan women were more
activated than those from US women, with elevated levels
of CD4+ CD69+, CD4+ CD69+ CCR5+ and CD8+ CD69+
T-cell subsets, possibly contributing to susceptibility and
the higher HIV incidence in young women from sub-
Saharan Africa. We have previously shown that levels of T-
cell activation in blood broadly correlate with activation in
T cells present in the female genital tract.30 Reduced fre-
quencies of susceptible HIV target cells in blood could
therefore influence the availability of these cells at the geni-
tal mucosa.
Exposed-uninfected individuals in this study had lower
concentrations of GM-CSF, IFN-c and IL-2 in plasma
than HIV-unexposed individuals. Both in vivo47 and
in vitro48 studies have shown that IL-2 increases CCR5
expression on T cells. Interferon-c influences the ability
of macrophages to present antigens, so could modulate
cell-to-cell spread of HIV.49 Furthermore, both IFN-c and
IL-2 increase the expression of HLA class II (including
HLA-DR) and enhance antigen presentation, so lower
concentrations of these cytokines in exposed–uninfected
individuals could contribute to lower cell surface expres-
sion of HLA class II.50 GM-CSF promotes activation,
maturation and differentiation of several immune cell
subsets, so reduced GM-CSF concentrations in exposed–
uninfected individuals compared with unexposed individ-
uals could also contribute directly to the lower T-cell
activation that we observed in this study. In a study by
Schramm et al.51, the cord blood plasma GM-CSF levels
were lower in exposed–uninfected infants who had HIV-
specific responses compared with exposed–uninfected
infants who did not have such responses. These levels
were also lower in exposed–uninfected infants when com-
pared with infants who became infected intrapartum or
unexposed infants.
In conclusion, this study showed lower levels of sys-
temic immune activation, CCR5 expression and lower
levels of plasma cytokines in HIV-exposed–uninfected
individuals, compared with HIV-unexposed individuals.
Lower availability of susceptible HIV target cells could
explain the apparent resistance of these individuals to
HIV infection, despite exposure. Elucidating the biological
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characteristics underlying resistance to or protection
against HIV infection could provide valuable insight on
the protective mechanisms that may be harnessed for the
development of new treatments and HIV prevention
strategies.
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